A5067964575- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Heat shock proteins research
- Radiomics and Machine Learning in Medical Imaging
- Extracellular vesicles in disease
- Helicobacter pylori-related gastroenterology studies
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Liver physiology and pathology
- Hydrogen's biological and therapeutic effects
- Endoplasmic Reticulum Stress and Disease
- Monoclonal and Polyclonal Antibodies Research
- Ovarian cancer diagnosis and treatment
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
Candiolo Cancer Institute
2011-2024
University of Turin
2011-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2023
University of Cagliari
2011
Abstract MicroRNAs (miRNA) are a recently identified class of noncoding, endogenous, small RNAs that regulate gene expression, mainly at the translational level. These molecules play critical roles in several biological processes, such as cell proliferation and differentiation, development, aging. It is also known miRNAs role human cancers where they can act either oncogenes, down-regulating tumor suppressor genes, or onco-suppressors, targeting critically involved promotion growth. One...
Studies on gene and/or microRNA (miRNA) dysregulation in the early stages of hepatocarcinogenesis are hampered by difficulty diagnosing lesions humans. Experimental models recapitulating human hepatocellular carcinoma (HCC) then used to perform this analysis. We performed miRNA and expression profiling characterize molecular events involved multistep process resistant-hepatocyte rat model. A high percentage dysregulated miRNAs/genes HCC were similarly altered preneoplastic positive for...
MET, the tyrosine kinase receptor for hepatocyte growth factor, is frequently overexpressed in colon cancers with high metastatic tendency. We aimed to evaluate role of its negative regulators, miR-1 and miR-199a*, transcriptional activator, metastasis-associated cancer 1 (MACC1), controlling MET expression human samples.The miR-1, MACC1 was evaluated by real-time PCR 52 matched pairs colorectal nontumoral surrounding tissues. The biological activity assessed cells either forced or...
Gastric cancer is the third most lethal worldwide, and evaluation of genomic status gastric cells has not translated into effective prognostic or therapeutic strategies. We therefore hypothesize that outcomes may depend on tumor microenvironment (TME), in particular, cancer-associated fibroblasts (CAF). However, very little known about role CAFs cancer. To address this, we mapped transcriptional landscape human stroma by microdissection RNA sequencing from patients with A stromal gene...
Gastric cancer is the second leading cause of mortality in world. The receptor tyrosine kinase MET constitutively activated many gastric cancers and its expression strictly required for survival some cells. Thus, considered a good candidate targeted therapeutic intervention this type tumor, inhibitors recently entered clinical trials. One major problems therapies targeting kinases that tumors are not responsive to treatment or eventually develop resistance drugs. Perspective studies thus...
The Yes-associated protein (YAP) is a transcriptional co-activator upregulating genes that promote cell growth and inhibit apoptosis. main dysregulation of the Hippo pathway in tumors due to YAP overexpression, promoting epithelial mesenchymal transition, transformation, increased metastatic ability. Moreover, it has recently been shown plays role sustaining resistance targeted therapies as well. In our work, we evaluated acquired epidermal factor receptor (EGFR) tyrosine kinase inhibitors...
Abstract Gastric cancer is the world's third leading cause of mortality. In spite significant therapeutic improvements, clinical outcome for patients with advanced gastric poor; thus, identification and validation novel targets extremely important from a point view. We generated wide, multilevel platform models, comprising 100 patient-derived xenografts (PDX), primary cell lines, organoids. Samples were classified according to their histology, microsatellite stability, Epstein–Barr virus...
Abstract Objectives Although the hepatomitogenic activity of triiodothyronine (T3) is well established, wide range harmful effects exerted by this hormone precludes its use in liver regenerative therapy. Selective agonists beta isoform thyroid receptor (TRβ) do not exhibit T3‐induced cardiotoxicity and show a good safety profile patients with NASH. The aim study was to investigate whether two novel TRβ agonists, prodrug TG68 active compound IS25 could stimulate hepatocyte proliferation...
Abstract Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy-number variation (CNV) and AMNESIA panel encompassing primary resistance alterations (KRAS/PIK3CA/MET mutations, KRAS/EGFR/MET amplifications) may patients’ selection for inhibition. Experimental Design: a post hoc analysis on 327 samples successfully sequenced by...
Abstract Despite negative results of clinical trials conducted on the overall population patients with gastric cancer, PARP inhibitor (PARPi) therapeutic strategy still might represent a window opportunity for subpopulation cancer. An estimated 7% to 12% cancers exhibit mutational signature associated homologous recombination (HR) failure, suggesting that these could potentially benefit from PARPis. To analyze responsiveness cancer PARPi, we exploited gastroesophageal adenocarcinoma (GEA)...
BACKGROUND Neuroendocrine differentiation in prostate cancer is a dynamic process associated to the onset of hormone-refractory disease vivo. The molecular mechanisms underlying this are poorly recognized. Our study aimed at testing vitro role hASH-1, transcription factor implicated neuroendocrine differentiation, phenotype cells. METHODS Androgen sensitive LNCAP, androgen insensitive PC-3, and three immortalized cell lines were cultured standard deprivation conditions. Expression hASH-1 was...
The onset of secondary resistance represents a major limitation to long-term efficacy target therapies in cancer patients. Thus, the identification mechanisms mediating is key rational design therapeutic strategies for resistant MiRNA profiling combined with RNA-Seq MET-addicted cell lines led us identify miR-205/ERRFI1 (ERBB receptor feedback inhibitor-1) axis as novel mediator MET tyrosine kinase inhibitors (TKIs). In cells MET-TKIs, epigenetically induced miR-205 expression determined...
Patient-Derived Xenografts (PDXs), entailing implantation of cancer specimens in immunocompromised mice, are emerging as a valuable translational model that could help validate biologically relevant targets and assist the clinical development novel therapeutic strategies for gastric cancer. More than 30% PDXs generated from carcinoma samples developed human B-cell lymphomas instead These were monoclonal, Epstein Barr Virus (EBV) positive, originated tumorigenic cell cultures displayed...
Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, outcome patients with advanced adenocarcinoma is poor. Randomized clinical trials failed to show a survival benefit in molecularly unselected treated anti-EGFR agents.
Abstract Background Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a poor prognosis for patients advanced disease. Since oncogenic role KRAS mutants has been poorly investigated in GC, this study aims to biochemically and biologically characterize different KRAS-mutated models unravel differences among response therapy. Methods Taking advantage proprietary, molecularly annotated platform more than 200 GC PDXs (patient-derived xenografts), we identified...
Adult hepatocytes are quiescent cells that can be induced to proliferate in response a reduction liver mass (liver regeneration) or by agents endowed with mitogenic potency (primary hyperplasia). The latter condition is characterized more rapid entry of into the cell cycle, but mechanisms responsible for accelerated S phase unknown.Next generation sequencing and Illumina microarray were used profile microRNA mRNA expression CD-1 mice livers 1, 3 6 h after 2/3 partial hepatectomy (PH) single...